After selling Elan's share in Tysabri, its multiple sclerosis drug, Martin is using the €3.25 billion in proceeds to reinvent the firm as a private equity-style acquisition vehicle - a high risk gamble sweetened with a recent €1 billion share buyback
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team